Article

Magnitude and Breadth of a Nonprotective Neutralizing Antibody Response in an Efficacy Trial of a Candidate HIV-1 gp120 Vaccine

Vaccine Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
The Journal of Infectious Diseases (Impact Factor: 5.78). 08/2010; 202(4):595-605. DOI: 10.1086/654816
Source: PubMed

ABSTRACT A candidate vaccine consisting of human immunodeficiency virus type 1 (HIV-1) subunit gp120 protein was found previously to be nonprotective in an efficacy trial (Vax004) despite strong antibody responses against the vaccine antigens. Here we assessed the magnitude and breadth of neutralizing antibody responses in Vax004.
Neutralizing antibodies were measured against highly sensitive (tier 1) and moderately sensitive (tier 2) strains of HIV-1 subtype B in 2 independent assays. Vaccine recipients were stratified by sex, race, and high versus low behavioral risk of HIV-1 acquisition.
Most vaccine recipients mounted potent neutralizing antibody responses against HIV-1(MN) and other tier 1 viruses. Occasional weak neutralizing activity was detected against tier 2 viruses. The response against tier 1 and tier 2 viruses was significantly stronger in women than in men. Race and behavioral risk of HIV-1 acquisition had no significant effect on the response. Prior vaccination had little effect on the neutralizing antibody response that arose after infection.
Weak overall neutralizing antibody responses against tier 2 viruses is consistent with a lack of protection in this trial. The magnitude and breadth of neutralization reported here should be useful for identifying improved vaccines.

Download full-text

Full-text

Available from: David C Montefiori, Apr 11, 2014
0 Followers
 · 
157 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The explosive proliferation of battery-powered equipment in the past decade has accelerated the development and usage of Low-Dropout voltage regulators (sometimes referred to as PNP voltage regulators). Compared to the standard NPN regulator, the Low-Dropout Regulator (LDO) can hold its output voltage in regulation with much less voltage across it: the NPN requires about 2 V of “headroom” to regulate, while the LDO will typically work with less than 500 mV of input-to-output voltage differential. The reduced input voltage requirement of an LDO is advantageous in battery-powered systems, since it translates directly into fewer battery cells, less wasted power, smaller size, and lower cost. The LDO's higher level of performance requires the use of external compensation capacitors, something an NPN regulator does not need. Also, the capacitors must be carefully selected for electrical parameters to assure stability. This article will develop an overview of LDO/NPN regulator theory, focusing on loop compensation and the parameters affecting regulator stability
    Wescon/97. Conference Proceedings; 12/1997
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper presents an approach of image velocity measurement by using both of spatial filter and correlation method. The goal is to achieve the accurate measurement of image velocity, which in fact presented difficulties in the existence of background. We show high accuracy by using the approached method as result.
    Instrumentation and Measurement Technology Conference, 2002. IMTC/2002. Proceedings of the 19th IEEE; 02/2002
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent findings have brought optimism that development of a successful human immunodeficiency virus type-1 (HIV-1) vaccine lies within reach. Studies of early events in HIV-1 infection have revealed when and where HIV-1 is potentially vulnerable to vaccine-targeted immune responses. With technical advances in human antibody production, clues about how antibodies recognize HIV-1 envelope proteins have uncovered new targets for immunogen design. A recent vaccine regimen has shown modest efficacy against HIV-1 acquisition. However, inducing long-term T and B cell memory and coping with HIV-1 diversity remain high priorities. Mediators of innate immunity may play pivotal roles in blocking infection and shaping immunity; vaccine strategies to capture these activities are under investigation. Challenges remain in integrating basic, preclinical and clinical research to improve predictions of types of immunity associated with vaccine efficacy, to apply these insights to immunogen design, and to accelerate evaluation of vaccine efficacy in persons at-risk for infection.
    Immunity 10/2010; 33(4):542-54. DOI:10.1016/j.immuni.2010.09.011 · 19.75 Impact Factor
Show more